Roflumilast (trade name Daxas) is a medication used to treat chronic obstructive pulmonary disease (COPD). It is a phosphodiesterase-4 inhibitor that is designed to reduce inflammation in the lungs, making it easier for people with COPD to breathe. Roflumilast was approved by the US Food and Drug Administration (FDA) in 2011 and is currently available in tablet form. It is usually taken once daily, with or without food. Common side effects include nausea, headache, and diarrhea. Roflumilast should not be used in people with severe liver or kidney problems.
Roflumilast is a medication used to treat chronic obstructive pulmonary disease (COPD). Here's a breakdown of its key features:
Therapeutic Use:
- Roflumilast is specifically indicated for severe COPD to reduce the frequency of exacerbations (flare-ups). COPD is a progressive lung disease that causes difficulty breathing. Exacerbations are worsening of symptoms that may require hospitalization.
Mechanism of Action:
- Unlike bronchodilators which directly open airways, Roflumilast works by decreasing inflammation in the lungs.
- It achieves this by inhibiting an enzyme called phosphodiesterase-4 (PDE4). PDE4 is present in immune and inflammatory cells in the lungs. By blocking PDE4, Roflumilast helps regulate inflammatory processes, leading to reduced lung inflammation associated with COPD.
Dosage and Administration:
- Roflumilast comes as a tablet taken orally, typically once a day with or without food.
- It's important to take Roflumilast consistently as directed by your doctor for it to be effective in preventing COPD exacerbations.
Important Considerations:
- Roflumilast is not a bronchodilator and won't relieve sudden shortness of breath or wheezing during an exacerbation. It's used for long-term management to prevent these episodes.
- It can cause side effects, including weight loss, diarrhea, nausea, and headache.
- Roflumilast may interact with other medications, so it's crucial to inform your doctor about all medications you're taking before starting Roflumilast.
Recent Developments:
- In addition to COPD, Roflumilast has recently been approved (December 2023) in a topical foam formulation for the treatment of seborrheic dermatitis, a type of scalp eczema, in patients aged 9 years and older.